Quick Answer
Arcturus Therapeutics Holdings Inc. reported Long Term Debt of $40.63 million for the year ending 2021.
- Arcturus Therapeutics Holdings Inc. showed an increase of +193.5% in Long Term Debt from 2020 to 2021.
- This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 29, 2023.
- XBRL data for this metric is available from 2018 to 2021 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $9.98 million | Q3 2019: $10.02 million | Q1 2020: $15.03 million | Q2 2020: $15.06 million | Q3 2020: $15.08 million | Q1 2021: $58.15 million | Q2 2021: $56.31 million | Q3 2021: $42.35 million | Q1 2022: $39.24 million | Q2 2022: $35.76 million | Q3 2022: $32.04 million | Q3 2023: $20.00 million | Q1 2025: $15.00 million.
- Over the full 4 years of available data (2018 to 2021), Arcturus Therapeutics Holdings Inc.'s Long Term Debt has grown by 310.0%.
- Historical annual values: Fiscal year 2021: $40.63 million | Fiscal year 2020: $13.85 million | Fiscal year 2019: $15.00 million | Fiscal year 2018: $9.91 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: